Discover 1,943 paid clinical trials in Fort Worth, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Fort Worth offers a range of medical research opportunities, focusing on conditions such as cancer, cardiovascular disease, PTSD, and COVID-19. Healthy volunteers looking for paid opportunities, as well as those with specific health concerns, can participate in studies at the city’s leading healthcare facilities, gaining access to new and innovative treatments while contributing to advancements in medical research.
Filter
2
Filter results
Results: 1,943
Active & Responsive
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
for
Insomnia
Location: DeSoto TX, Oklahoma City OK, Houston TX, Savannah GA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18 - 70
Code: NCT06655883
Phase 3, Recruiting
Active & Responsive
A Study of Brenipatide in Participants With Opioid Use Disorder
for
Opioid Use Disorder
Location: DeSoto TX, Houston TX, Little Rock AR, Ridgeland MS,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07420283
Phase 2, Recruiting
Active & Responsive
52-week Open Label Safety-Tolerability Study
for
Schizophrenia
Location: DeSoto TX, Richardson TX, Cerritos CA, Bentonville AR,
Sponsor: LB Pharmaceuticals Inc.
Sex: All
Age: 18 - 65
Code: NCT07369154
Phase 3, Recruiting
Active & Responsive
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Evaluation of Liver Stiffness Performance, by FibroScan®, to Detect Elevated Central Venous Pressure (CVP)
for
Heart Failure, Heart Failure - NYHA II - IV
Location: Dallas TX, Minneota MN, Charleston SC
Sponsor: Echosens
Sex: All
Age: 18+
Code: NCT07222813
Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Dallas TX, Houston TX, St Louis MO, Denver CO,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase 1, Recruiting
Active & Responsive
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates